Zalecane piśmiennictwo

1. Arends M, van Dussen L, Biegstraaten M, et al. Malignancies and monoclonal gammopathy in Gaucher disease: a systematic review of the literature. Br J Haematol 2013;161(6):832-42

2. Belmatoug N, Di Rocco M, Fraga C, et al. Management and monitoring recommendations for the use of eliglustat in adults with type I Gaucher disease in Europe. Eur J Intern Med 2017;37:25-32

3. Beutler E. Gaucher disease: multiple lessons from a single gene disorder. Acta Paediatr Suppl 2006;95(451):103-9

4. Grabowski GA. Phenotype, diagnosis and treatment of Gaucher disease. Lancet 2008;372(9645):1263-71

5. Hughes D, Capellini MD, Berger M, et al. Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol 2007;138(6):676-86

6. Kaplan P, Andersson HC, Kacena HA, et al. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med 2006;160(6):603-8

7. Machaczka M. Allogeneic hematopoietic stem cell transplantation for treatment of Gaucher disease. Pediatr Hematol Oncol 2013;30(5):459-61

8. Mikosch P, Hughes D. An overview on bone manifestations in Gaucher disease. Wien Med Wochenschr 2010;160(23-24):609-24

9. Mistry PK, Capellini MD, Lukina E, et al. A reappraisal of Gaucher disease – diagnosis and management algorithms. Am J Hematol 2011;86(1):110-5

10. Oeda T, Umemura A, Mori Y, et al. Impact of glucocerobrosidase mutasions on motor a nonmotor complications in Parkinson’s disease. Neurobiol Aging 2015;36(12):3306-13

11. Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin in Hematology 2004;41(4 Suppl 5):4-14

12. Revel-Vilk S, Szer J, Mehta A, et al. How we manage Gaucher disease in the era of choices. Br J Haematol 2018;182(4):467-80

13. Rosenbloom BE, Weinreb NJ. Gaucher disease: a comprehensive review. Crit Rev Oncog 2013;18(3):163-75

14. Turkia HB, Gonzalez DE, Barton NW, et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. Am J Hematol 2013;88(3):179-84

15. Tylki-Szymańska A, Vellodi A, El-Beshlawy A, et al. Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry. J Inherit Metab Dis 2010;33(4):339-46

16. Zimran A. How I treat Gaucher disease. Blood 2011;118(6):1463-71

17. Zimran A. Survey of hematological aspects of Gaucher disease. Hematology 2005;10(2):151-6